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DOI 10.1016/j.ccr.2011.12.006SUMMARYConstitutive Kras and NF-kB activation is identified as signature alterations in pancreatic ductal adenocarci-
noma (PDAC). However, how NF-kB is activated in PDAC is not yet understood. Here, we report that
pancreas-targeted IKK2/b inactivation inhibited NF-kB activation and PDAC development in KrasG12D and
KrasG12D;Ink4a/ArfF/F mice, demonstrating a mechanistic link between IKK2/b and KrasG12D in PDAC incep-
tion. Our findings reveal that KrasG12D-activated AP-1 induces IL-1a, which, in turn, activates NF-kB and its
target genes IL-1a and p62, to initiate IL-1a/p62 feedforward loops for inducing and sustaining NF-kB
activity. Furthermore, IL-1a overexpression correlates with Krasmutation, NF-kB activity, and poor survival
in PDAC patients. Therefore, our findings demonstrate the mechanism by which IKK2/b/NF-kB is activated
by KrasG12D through dual feedforward loops of IL-1a/p62.INTRODUCTION Several previous studies have shown a key role of the NF-kBThemutational activation ofKras is an early event in PDACdevel-
opment and has been detected in 80%–95% of PDAC, and
mutational inactivation of Ink4a/Arf tumor suppressor genes
can be identified in approximately 50%–75% of PDAC (Hruban
et al., 2000). Several experimental animal models were estab-
lished to determine the functions of mutated Kras in induction
of pancreatic intraepithelial neoplasia (PanIN) and PDAC (Aguirre
et al., 2003; Bardeesy et al., 2006; Hingorani et al., 2003).
However, the key signaling pathways that function downstream
of Kras remained unidentified.Significance
Pancreatic ductal adenocarcinoma (PDAC) is the fourth most
survival rate has remained 1%–3% for the past 25 years. Eac
over 80% are therapy-resistant locally advanced or metastati
PDAC remains a challenge in cancer research. To understan
IKK2/b/NF-kB activation and KrasG12D mutation, two of the si
neered mouse models. Our findings establish a pathway lin
IKK2/b/NF-kB is activated by KrasG12D; this suggests therape
Csignaling pathway in Ras-driven cancers using animal models
of cancer. For example, knockout of IKK2/b inhibited H-Ras-
driven melanoma (Yang et al., 2010), inhibition of NF-kB
bypassed restraints on oncogenic Ras-stimulated growth in
induction of invasive human epidermal neoplasia (Dajee et al.,
2003), and loss of IKK2/b in hepatocyte enhances inflammation,
tumor promotion, and progression (He et al., 2010; Maeda et al.,
2005). We previously showed that RelA/p50NF-kB is constitu-
tively activated in almost 70% of pancreatic cancer specimens
and inhibition of NF-kB activity by a mutant IkBa inhibited
PDAC cell tumorigenesis (Fujioka et al., 2003; Wang et al.,common cause of adult cancer death in the US. The 5-year
h year approximately 42,000 cases of PDAC are diagnosed;
c disease, and median survival is less than 6 months. Thus,
d mechanisms of pancreatic tumorigenesis, we examined
gnature alterations in human PDAC, using genetically engi-
king dual feedforward loops of IL-1a/p62 through which
utic targets for inhibiting KrasG12D signaling in PDAC.
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KrasG12D-Induced IKK2 Activation and Tumorigenesis1999). Thus, these studies demonstrated that IKK2/b/NF-kB has
a distinct function in different types of cells. However, it was
unclear whether IKK2/b/NF-kBhas either prooncogenic or tumor
suppressive role in mutant Kras-induced PDAC in mouse
models.
Accumulating evidence shows that various signals, including
mutant Kras and cytokines activate NF-kB, which, in turn, inte-
grates proinflammatory signals and promote tumorigenesis
(Staudt, 2010). For instance, binding of interleukin-1alpha (IL-
1a) to its receptor induces K63-linked polyubiquitination of tumor
necrosis factor (TNF) receptor-associated factor 6 (TRAF6)
and activates transforming growth factor-b-activated kinase 1
(TAK1), which induces activation of IKK2/b, c-Jun N-terminal
kinase, and p38 MAPK to activate NF-kB and AP-1 (Skaug
et al., 2009; Wang et al., 2001). The turnover of signal-induced
K63-polyubiquitination of TRAF6 is prevented by signaling
adaptor p62 to prolong IKK2/b and NF-kB activation (Wooten
et al., 2005), Furthermore, p62 is an important NF-kB mediator
in lung tumorigenesis (Duran et al., 2008), However, the mecha-
nisms that regulate p62 to control IKK2/b activation to the extent
of stimulation were unknown. Another report showed that
mutant Kras-driven transformation requires TBK1 kinase activa-
tion (Barbie et al., 2009). However, the work did not reveal the
mechanisms for constitutive NF-kB activation by TBK1 inmutant
Kras-driven tumor. Studies showed that mutant Kras-associated
RAL guanine nucleotide exchange factors promote TBK1 kinase
activation via an unknown mechanism, which, in turn, activates
c-rel/p50NF-kB, (Chien et al., 2006), and that kinase-inactive
TBK1 inhibits TANK-mediated alternative NF-kB activation
pathway, but does not block canonical NF-kB activation induced
by TNF-a or IL-1 (Pomerantz and Baltimore, 1999). Thus, the
mechanisms through which oncogenic Kras activates the
canonical NF-kB pathway in PDAC remained unknown.
In the present study, we investigated the role of IKK2/b/NF-kB
activation and expression of IL-1a and p62 in KrasG12D-induced
PDACdevelopment and explored the underlyingmechanisms by
which IKK2/b/NF-kB is activated by KrasG12D.
RESULTS
Generation of Mutant Mouse Strains with Pancreas-
Specific Expression of KrasG12D and Inactivation
of IKK2/bwith or without Concurrent Ink4a/Arf Deletion
To determine the function of constitutive NF-kB activity in PDAC
development, we targeted IKK2/b deletion in the pancreas of
the KrasG12D mice with and without Ink4a/Arf inactivation. The
mouse strain with floxed IKK2/b alleles (IKK2/bF/F) (Li et al.,
2003) is utilized in breedingwith themice that harbors aPdx1-Cre
transgene (Pdx1-Cre) (Gu et al., 2002) and a latent KrasG12D
knockin allele (KrasLSL-G12D) (Hingorani et al., 2003), and
those that carry the floxed Ink4a/ Arf (Ink4a/Arf F/F), KrasLSL-G12D,
and Pdx1-Cre alleles (Aguirre et al., 2003). Generation of IKK2/
bF/F genotypes in Pdx1-Cre;KrasLSL-G12D and Pdx1-Cre;
KrasLSL-G12D;Ink4a/ArfF/F strains are schematically depicted in
Figure 1A. Cre-mediated excision of the silencing cassette and
subsequent recombination generated a single LoxP site was
detected in the pancreas, but not in other organs such as liver
in all of the mouse lines (Figure 1B). Consistent with expression
of the mutant Kras allele at endogenous level, GTP-bound Ras106 Cancer Cell 21, 105–120, January 17, 2012 ª2012 Elsevier Inc.protein was increased only in protein extracts from the pancreata
of the mice carrying Pdx1-Cre;KrasLSL-G12D alleles (Figure 1C).
The third coding exon-deleted IKK2/b alleles were detected in
a mosaic pattern in the pancreata of all Pdx1-Cre;IKK2/bF/F
mice (Figure 1D). As a result, NF-kB DNA binding activities
were notably reduced in nuclear extracts from the pancreata
of Pdx1-Cre;KrasLSL-G12D;IKK2/bF/F mice, but not in those of
Pdx1-Cre;KrasLSL-G12D mice (Figures 1E and 1F). Both
p16Ink4a and p19Arf genes were specifically deleted in the pan-
creata of the mutant mice (Figure 1G). Thus, these results show
that the Pdx1-Cre transgene concurrently deleted LoxP-contain-
ing alleles to target expression of KrasG12D and inactivation of
IKK2/bF/F and/or Ink4a/ArfF/F alleles specifically in the pancreata
of these mutant mice.
IKK2/b Activity Required for Oncogenic Kras-Induced
PanIN and PDAC
To examine the role of IKK2/b in PDAC development, we charac-
terized a cohort of Pdx1-Cre;KrasLSL-G12D;IKK2/bF/F and Pdx1-
Cre;KrasLSL-G12D;Ink4a/ArfF/F;IKK2/bF/F mice and their control
littermates. Our findings revealed that these mutant mice did
not develop PDAC, unlike their control mice (Figures 2A and
2B). Chi-square analysis showed that the Pdx1-Cre;KrasLSL-G12D
genotypes with IKK2/b are associated with the observed
chronic pancreatis (CP), PanIN lesions, cystic ductal lesion
(CDL), and PDAC (Figure 2B), suggesting IKK2/b plays a causal
role in PDAC development. Consistent with these results, Pdx1-
Cre;KrasLSL-G12D;Ink4a/ArfF/F;IKK2/bF/F mice remained free of
PDAC for over 12 months, whereas the median survival of
Pdx1-Cre;KrasLSL-G12D;Ink4a/ArfF/F mice was about 3.5 months,
as previously described (Aguirre et al., 2003; Figure 2C).
The littermates of all the mutant mice were born with
mendelian frequencies and weight similar to those of wild-type
controls. Organs appeared to be formed normally and no pheno-
typic differences were observed before the age of 2 months
in Pdx1-Cre;KrasLSL-G12D mice and 6 weeks in Pdx1-Cre;
KrasLSL-G12D;Ink4a/ArfF/F mice. No pancreatic ductal lesions or
other abnormalities were detected and the expression levels of
glucagon, insulin, amylase, CK-19, and staining of duct-specific
lectins, Dolichos biflorus agglutinin (DBA) in various IKK2/bF/F
mice are consistent with those observed in the pancreas of
wild-type mice (Figures 2E and 2F; Figure S1 available online).
Altogether, the normal histology, marker gene expression, and
life span suggest that knockout of IKK2/b in mouse pancreas
did not result in abnormal pancreas development in acinar,
ductal, and islet of the pancreas or apparent pathological
phenotypes.
In Pdx1-Cre;KrasLSL-G12D;IKK2/bF/F mice (Figures 2F and 2G),
only 12% (10 of 84) of the mice developed stage 1 PanIN
lesions, which consisted primarily of elongated mucinous ductal
cells, and no PDAC was observed for over 12 months, whereas
19% (13 of 70) of Pdx1-Cre;KrasLSL-G12D mice had PDAC in
8–12 months (Figure 2M), 24% (17 of 70) had CDL during the
same time period (Figure 2L), and 27% (19 of 70) had stage 1,
2, or 3 PanIN lesions (Figures 2I–2K) at about 3–6 months.
Moreover, most CP was associated with all the PanIN and
PDAC, and only 10% of Pdx1-Cre;KrasLSL-G12D mice (7 of 70)
developed CP without PanIN or PDAC pathological lesions
(Figures 2A and 2H). These findings suggest that inactivation of
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Figure 1. Generation of Mouse Strains with Pancreas-Specific KrasG12D Expression and Inactivation of IKK2/b with or without Parallel
Deletion of Ink4a/Arf
(A) Graphic representation of the targeted KrasLSL-G12D, IKK2/b, and Ink4a/Arf alleles before and after Cre-mediated excision and recombination.
(B) The presence of recombined KrasG12D allele in the pancreata (P) but not in the livers (L) of compound mutant mice was revealed by PCR.
(C) Ras-GTP and total Ras levels in whole pancreatic protein extracts of 3-month-old Pdx1-Cre;KrasLSL-G12D, Pdx1-Cre;KrasLSL-G12D;IKK2/bF/F, and Pdx1-Cre;
IKK2/bF/F mice. Elevated levels of Ras-GTP were observed only in compound mutant mice with Pdx1-Cre;KrasLSL-G12D alleles.
(D) The recombined IKK2/bF/F allele was detected only in the pancreata (P), not in the livers (L), of mice carrying Pdx1-Cre;IKK2/bF/F alleles.
(E) EMSA was performed to determine the levels of NF-kB DNA binding activity in the pancreata carrying Pdx1-Cre;KrasLSL-G12D, Pdx1-Cre;KrasLSL-G12D;IKK2/
bF/F, orPdx1-Cre;IKK2/bF/F alleles. Nuclear extracts frommouse pancreata were used in this analysis with a kBprobe. Oct-1 probe was used as a loading control.
(F) EMSA was performed with 32P-labeled kB probe in the presence and absence of both unlabeled wild-type (WT) and mutant (Mu) kB probes to determine the
specificity of NF-kB DNA binding activity detected in the pancreata of Pdx1-Cre;KrasLSL-G12D mice as indicated.
(G) Pancreas-specific deletion of Ink4a/Arf alleles was confirmed in Pdx1-Cre; KrasLSL-G12D;IKK2/bF/F;Ink4a/ArfF/F mice. The presence of the recombined
KrasG12D allele and the exon 3-deleted IKK2/b allele in the pancreata (P) (lane 5) but not in the livers (L) (lane 6) of compound mutant mice was revealed by PCR.
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Figure 2. Suppression of Oncogenic KrasG12D-Induced Histological Progression of PanIN and PDAC with or without Concurrent Deletion of
Ink4a/Arf by Inactivation of IKK2/b
(A) Numbers of mutant mice that developed PDAC, cystic ductal lesions (CDL), PanIN, or chronic pancreatitis (CP), or remained healthy, in cohorts of Pdx1-
Cre;KrasLSL-G12D, Pdx1-Cre;KrasLSL-G12D;IKK2/bF/F, and Pdx1-Cre;IKK2/bF/F mice.
(B) Chi-square analysis of the association between Pdx1-Cre;KrasLSL-G12D and Pdx1-Cre;KrasLSL-G12D;IKK2/bF/F, and the observed phenotypes in (A). Note: CP
was found in PanIN, CDL, and PDAC; PanIN was coexisted with CDL and PDAC; and CDL was observed in PDAC.
(C) Kaplan-Meier PDAC-free survival curve for Pdx1-Cre;KrasLSL-G12D;Ink4a/ArfF/F (n = 16) and Pdx1-Cre;KrasLSL-G12D;IKK2/bF/F;Ink4a/ArfF/F mice (n = 15).
According to the approved animal protocol, mice that presented in a moribund state were killed for autopsy.
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KrasG12D-Induced IKK2 Activation and TumorigenesisIKK2/b inhibited PDAC and CP might be a precursor lesion in
Kras-induced PDAC.
Serial histological surveys of the pancreas of all the mice are
shown in Figures 2D–2S. Pdx1-Cre;KrasLSL-G12Dmice had PanIN
at 3months of age and had invasive tumors by 10months of age,
and 3 of 70 had liver or lungmetastatic lesions by 8–12months of
age (Figures 2N and 2O). The progressive premalignant lesions
with ductal histology and PDAC were observed (Figures 2M–
2O and 2R). These PDAC histological lesions and incidences
are consistent with those of the mice harboring KrasLSL-G12D or
KrasLSL-G12D;Ink4a/ArfF/F in earlier studies (Aguirre et al., 2003;
Tuveson et al., 2004). These results demonstrate that IKK2/b is
required for oncogenic Kras-induced PanIN and PDAC, thus
establishing a definitive role of IKK2/b in PDAC development
in vivo.
Attenuation of Inflammatory and Proliferative
Responses by Pancreas-Targeted Inactivation of IKK2/b
To determine whether chronic inflammation and proliferative
responses were inhibited in the pancreas of Pdx1-Cre;
KrasLSL-G12D;IKK2/bF/F mice, immunohistochemical (IHC) anal-
yses were performed. Levels of proliferation markers CyclinD1,
Ki-67, and inflammatory marker COX-2 expression were sub-
stantially higher in PanIN and PDAC from Pdx1-Cre;KrasLSL-G12D
mice, than in histologically normal pancreas from Pdx1-Cre;
KrasLSL-G12D;IKK2/bF/F mice (Figure 3A). This finding suggests
that inactivation of IKK2/b interrupted mutant Kras-stimulated
cell proliferation and inflammation.
The observation of CP or proinflammatory responses in
Pdx1-Cre;KrasLSL-G12D mice prompted us to examine whether
these mutant mice developed lymphocytic infiltration around
pancreatic lesions. IHC staining revealed that the infiltrating
lymphocytes consisted of CD3-positive T cells, B220-positive
B cells, F4/80-positive macrophages, and Ly6g-positive neutro-
phil (Figure 3B), whereas parallel staining did not reveal signifi-
cant lymphocytic infiltration in the pancreata of Pdx1-Cre;
KrasLSL-G12D;IKK2/bF/F mice (Figure 3B). This phenotype of lym-
phocytic infiltration in the pancreata of Pdx1-Cre;KrasLSL-G12D
mice has a close resemblance to those reported for various
mouse strains with pancreatitis, such as IkBam/m mice defective
in IkBa-mediated negative regulation of NF-kB (Peng et al.,
2010). So, the absence of hallmarks of cancer-related inflamma-
tion in Pdx1-Cre;KrasLSL-G12D;IKK2/bF/F mice is due to inactiva-
tion of IKK2/b. This suggests chronic inflammation is a key factor
in promoting PDAC development as observed in mouse models
for other cancers (Karin, 2008), and one of the essential roles
regulated by IKK2/b in Kras-induced PDAC inception.
Inhibition of Key Proinflammatory Cytokines in the
Pancreas of Pdx1-Cre;KrasLSL-G12D;IKK2/bF/F Mice
To further analyze Kras-induced inflammatory responses, gene
expression was profiled and a number of known and previously(D–S) Representative pancreatic histologic views. (D) Normal pancreas from
Pdx1-Cre;IKK2/bF/F mouse. (F) Histologic appearance of normal pancreas from
KrasLSL-G12D;IKK2/bF/F mouse. (H–O) Pdx1-Cre;KrasLSL-G12D mice. (H) Chronic
(M) PDAC. (N) PDAC liver metastasis. (O) PDAC lung metastasis. (P-R) Pdx1-Cre
(S) Histologic appearance of normal pancreas from a Pdx1-Cre;KrasLSL-G12D;Ink4
See also Figure S1.
Cunknown NF-kB regulated genes were identified by Gene Set
Enrichment analyses (GSEA) using gene ontology and NF-kB
target gene sets (Figures 4A and 4B; Figures S2A–S2E). Impor-
tantly, GSEA of significant gene upregulation in Pdx1-Cre;
KrasLSL-G12D revealed that they are strongly associated to posi-
tive nodal status, high risk, higher tumor stage, and poor survival
in PDACpatients by comparing with 102 PDAC cDNAmicroarray
files (GSE21501) (Figure 4C). Two- and 5-fold enriched expres-
sion in Pdx1-Cre;Kras LSL-G12D;IKK2/bF/F is correlated to low
risk (Figures S2A–S2E). These findings further indicate that the
significant role of activated IKK2/b in PDAC development.
To further explore the role of IKK2/b in PDAC development, we
compared additional gene expression profiles from Pdx1-Cre;
KrasLSL-G12D and Pdx1-Cre;KrasLSL-G12D;IKK2/bF/F mice using
Affymetrix arrays. Our results showed that there is a little differ-
ence between the expression profiles of several IKK2/b/NF-
kB-regulated genes, such as IL-1a, IL-1b, and c-jun in the
histologically normal pancreas from Pdx1-Cre;KrasLSL-G12D and
Pdx1-Cre;KrasLSL-G12D;IKK2/bF/F mice, which might be due to
the small fractions of Pdx1-targed cells (Figures S2F and S2G;
Table S1). Furthermore, the analysis of the gene expression
profiles among the normal pancreas, PanIN, and PDAC from
Pdx1-Cre;KrasLSL-G12D mice revealed that these profiles are
consistent with those involved in PDAC development as those
identified between Pdx1-Cre;KrasLSL-G12D and Pdx1-Cre;
KrasLSL-G12D;IKK2/bF/F mice (Figures 4A–4C; Table S2), and are
associated with signaling pathways and cellular functions of
genes in tumorigenesis (Figures S2H and S2I). The progressive
increases in the expression of several NF-kB regulated genes
from low expression in the histological normal pancreas to
high expression levels in PanIN and PDAC suggest the involve-
ment of the NF-kB-regulated genes in Kras-induced PDAC
development.
Among 20 of the differentially expressed genes with a greater
than 10-fold increases in expression in the pancreatic tissues
of Pdx1-Cre;KrasLSL-G12D mice (Figure 4A), most of them are
cytokines, chemokines, and their receptors, suggesting a role
of these molecules in Kras-induced PDAC in vivo. To substan-
tiate the differences in cytokine gene expression between 5- to
12-month-old Pdx1-Cre;KrasLSL-G12D and age-matched Pdx1-
Cre;KrasLSL-G12D;IKK2/bF/F mice, we performed real-time PCR
arrays with 84 cytokines and chemokines and validated 9 cyto-
kines with highest expression levels, which includes IL-1a,
IL-1b, and IL-1 receptor type 2 (Figure 4D; Table S3).
We next investigate the expression of IL-1a and IL-1b, since
the expression of both cytokines is among the highest. The levels
of IL-1a were significantly elevated in pancreatic tissues and IL-
1b levels were slightly higher in serum of Pdx1-Cre;KrasLSL-G12D
mice, but not in wild-type, Pdx1-Cre;IKK2/bF/F, and Pdx1-Cre;
KrasLSL-G12D;IKK2/bF/F mice (Figures 4E and 4F). These results,
together with the lymphocytic infiltration, are consistent with
chronic inflammation and the role of IKK2/b in cytokinea wild-type mouse. (E) Histologic appearance of normal pancreas from a
a Pdx1-Cre;KrasLSL-G12D;IKK2/bF/F mouse. (G) A rare PanIN-1 from Pdx1-Cre;
pancreatitis (I) PanIN-1. (J) PanIN-2. (K) PanIN-3. (L) Cystic ductal lesion.
;KrasLSL-G12D;Ink4a/ArfF/F mice. (P) PanIN. (Q) Cystic ductal lesion. (R) PDAC.
a/ArfF/F;IKK2/bF/F mouse.
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Figure 3. Comparison of the Cell Prolifera-
tion, Inflammation, and Immune Responses
in the Pancreas between Pdx1-Cre;
KrasLSL-G12D;IKK2/bF/F and Pdx1-Cre;
KrasLSL-G12D Mice
(A) Expression of CyclinD1, Ki-67, and COX-2 is
elevated in PanIN and PDAC from Pdx1-Cre;
KrasLSL-G12D mice, but not in the normal pancreas
of Pdx1-Cre;KrasLSL-G12D;IKK2/bF/F mice. Positive
immunostaining for Cytokeratin-19 (CK-19)
verifies the ductal phenotype of PanIN lesions,
PDAC, and normal duct.
(B) Sections of formalin-fixed PanIN lesions and
PDAC from 8-month old Pdx1-Cre;KrasLSL-G12D
and normal duct tissue from Pdx1-Cre;
KrasLSL-G12D;IKK2/bF/F mice underwent IHC stain-
ing with anti-CD3 antibody as a T cell marker, anti-
B220 as a B cell marker, anti-F4/80 as a macro-
phage marker, and anti-Ly6g as a neutrophil
marker. Error bars represent ± standard deviation
(SD) from the data of five mice for each of the two
genotypes.
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environment. IL-1a is an NF-kB target gene and a strong NF-kB
inducer (Mori and Prager, 1996; Osborn et al., 1989), but IL-1a
induction by Kras is previously unknown, suggesting a possible110 Cancer Cell 21, 105–120, January 17, 2012 ª2012 Elsevier Inc.mechanistic link between IL-1a expres-
sion induced by the KrasG12D and IKK2/
b/NF-kB activation.
Downregulation of Expression of
IKK2/b/NF-kB Upstream Signaling
Molecules by Inactivation of IKK2/b
To elucidate the downstream pathways
of mutant Kras that activate IKK2/b, we
carried out IHC analysis of PanIN and
PDAC to determine the status of inflam-
mation related signaling pathways,
including TAK1, p65/RelA, c-Fos, p62,
IL-1a, and Rantes (Chemokine [C-C
motif] ligand 5). Our results show that
levels of c-Fos, TAK1, p62, activated-
p65/RelA, IL-1a, and Rantes were
substantially higher in PanIN and PDAC
from Pdx1-Cre;KrasLSL-G12D mice than in
histologically normal pancreata from
Pdx1-Cre;KrasLSL-G12D;IKK2/bF/F mice
(Figure 5A). These results suggest that
IKK2/b regulates the expression of
TAK1, p62, c-Fos, IL-1a, and Rantes as
well as NF-kB activation in the diseased
pancreas of Pdx1-Cre;KrasLSL-G12D
mice. To determine whether the Kras-
induced signaling pathways are also acti-
vated in human PDAC, IHC staining was
performed using six different PDAC
patient specimens with their adjacent
normal tissues as controls for a pilot
study. The increased levels of IL-1a,TAK1, c-Fos, nuclear p65/RelA recognized by a specific antiac-
tivated p65/RelA antibody (Zabel et al., 1993), p62, and phos-
phorylated AKT were observed in human PDAC (Figure 5B).
Taken together, these results suggest that inactivation of
Cancer Cell
KrasG12D-Induced IKK2 Activation and TumorigenesisIKK2/b interrupts oncogenic Kras-mediated pathways regulating
expression of c-Fos, IL-1a, TAK1, and p62, and activation of AKT
and NF-kB, but how these signaling molecules are regulated
by oncogenic Kras through IKK2/b pathways remained largely
unclear.
IL-1a Overexpression Correlates with Kras Mutation
and NF-kB Activation in Human PDAC Specimens
and Poor Survival in PDAC Patients
To determine whether IL-1a overexpression is correlated with
mutant Kras in human PDAC specimens, and is induced by
KrasG12D in mouse PanIN and PDAC, we sequenced the Kras
gene from paraffin sections of PDAC specimens from 14 patients
who had not undergone neoadjuvant therapies, and from 9
PDAC patient specimens derived from the orthotopic xenograft
mouse model implanted with freshly isolated patient pancreatic
cancer for excluding normal human stromal cells (Kim et al.,
2009). Ninety-three percent (13 of 14) Kras gene from PDAC
paraffin sections has substitutional mutation at codon 12, from
GGT (Gly) to GAT (Asp). 71% (5 of 7) Kras mutations identified
in human PDAC tissue xenograft also have aspartic acid at
codon 12, whereeas 29% (2 of 7) were changed to GTT (valine).
The results of IL-1a expression, analyzed by chi-square test,
showed that the presence of mutated Kras gene positively
correlatedwith IL-1a overexpression in PDACpatient specimens
(Figure 6A). Further study of IL-1a expression using human
PDAC tissue microarray (TMA) demonstrated that IL-1a over-
expression was found in most of the human PDAC tissues.
Kaplan-Meier survival analysis indicated that high levels of
IL-1a expression are associated with poor survival in PDAC
patients (p = 0.016, log rank test) (Figure 6B).
To determine the association between NF-kB activity and
expression levels of IL-1a in human PDAC for validating the
relevance of the observations in Pdx1-Cre;KrasLSL-G12D and
Pdx1-Cre; KrasLSL-G12D;IKK2/bF/F mice, IHC staining for p65
and IL-1a in patient PDAC TMA was performed. 42 of 131
(32%) human PDAC samples showed very strong IL-1a staining
and 47 (36%) had extremely intense staining for NF-kB activities
(Figure 6C). Data analysis of these by Spearman’s rank order
correlation showed the positive correlation between NF-kB
activities and expression levels of IL-1a (Figure 6D). Altogether,
the results suggest that the oncogenic Kras-mediated pathway
induced IL-1a overexpression, which triggered NF-kB activa-
tion. To determine how early activated NF-kB can be detected
during PDAC development, we analyzed the staining of p65/
RelA in our pancreatic TMA, and the results show 49% (20/41)
positive staining in PanIN stage (Figures S3A and S3B), suggest
that NF-kB activation is one of the earliest molecular alterations
observed in the development of pancreatic cancer.
To determine whether expression of IL-1a and p62 was
induced in by KrasG12D, we examined the levels of IL-1a and
p62 expression in human PDAC cell lines MDAPanc-28,
AsPc-1, and in immortalized human pancreatic ductal cell lines
HPDE and HPNE, with or without stable expression of mutant
Kras. Expression of both IL-1a and p62 was elevated in
MDAPanc-28 and AsPc-1 cells (Figure 6E) and in HPDE and
HPNE cells expressing oncogenic Kras (Figure 6F). The expres-
sion of c-Fos and activation of Jun N-terminal kinase (JNK) was
also induced in mutant Kras HPNE cells (Figure S3C).CTo determine whether oncogenic Kras-induced AP-1 activity
played a major role in the IL-1a and p62 expression, we per-
formed IL-1a and p62 promoter analysis in mPDAC cells, an
early passage mouse PDAC cell lines established from the
PDAC of Pdx1-Cre;KrasLSL-G12D mice. Our reporter gene assays
show that IL-1a promoter with mutated AP-1 sites had no
responses, whereas activity of IL-1a promoter with wild-type
AP-1 sites was strongly inhibited by expression of a mutant of
ras (RasN17), c-fos (FosDN), and IkBa (IkBaM), as well as
kinase-dead raf and jnk (Figure 6G). Similarly, p62 promoter
was strongly inhibited by expression of FosDN and IkBaM (Fig-
ure 6H). The results showed that IL-1a and p62 promoters in
mPDAC cells were regulated by Kras through AP-1 and NF-kB
transcription factors.
Identifying Feedforward Mechanisms that Sustain
Constitutive NF-kB Activation in Oncogenic
KrasG12D-Induced PDAC
To determine whether IL-1a serves a mechanistic link between
KrasG12D and NF-kB activation, we utilized two human PDAC
cell lines and two early passage mouse PDAC cell lines,
mPDAC-1 and mPDAC-2, which were established from PDAC
of Pdx1-Cre;KrasLSL-G12D mice. These cells were treated with
anti-IL-1a and anti-IL-1b neutralizing antibodies for 0, 4, and
8 hr and the nuclear extracts were analyzed. The results showed
that anti-IL-1a, but not anti-IL-1b, neutralizing antibodies
blocked constitutive NF-kB activation (Figures 7A and 7B).
These findings suggest that secreted IL-1a from these cells acti-
vates NF-kB through autocrine mechanism.
Although p62 was induced by Kras to trigger IKK2/b activation
in lung cancer cells (Duran et al., 2008), the mechanisms are
still lacking. To determine whether and how p62 is involved
in KrasG12D-induced IKK2/b/NF-kB activation, we stimulated
p62-knockdown cells and control cells expressing a puromycin
resistant vector and scrambled shRNA with IL-1a for 0, 0.5, 2,
or 8 hr and then analyzed NF-kB activity by EMSA (Figures 7C
and 7D). The results revealed that constitutive NF-kB activity
was decreased in both mPDAC and AsPc-1 p62 knockdown
cells (Figure 7D; Figures S4A and S4B). Interestingly, NF-kB
activity was induced to the same peak level by IL-1a at 0.5 hr
stimulation in the control and p62 knockdown cells, remained
at the same level at the end of 2 hr stimulation, and was inhibited
at the end of 8 hr of IL-1a stimulation for the p62 knockdown cells
compared with their control cells (Figure 7D; Figures S4A
and S4B). These findings suggest that p62 expression is
dispensable for IL-1a-induced NF-kB activation at the early
phase (Figure 7D, lanes 4–9; Figures S4A and S4B), but is
required for IL-1a-induced long-term NF-kB activation (Fig-
ure 7D, lanes 10–12; Figures S4A and S4B). Since p62 expres-
sion was substantially increased in PanIN and PDAC from
Pdx1-Cre;KrasLSL-G12D mice in comparison to those from histo-
logically normal pancreata from Pdx1-Cre;KrasLSL-G12D;IKK2/
bF/F mice (Figures 5A and 5B), it is possible that p62 is one of
the previous unknown downstream target genes regulated by
NF-kB. To test this possibility, we showed p62 expression was
substantially inhibited in MDAPanc-28 and AsPc-1 cells by
expressing IkBaM in comparison with their control cells (Fig-
ure 7E). Our results also show that both p62 mRNA and protein
levels were increased by IL-1a stimulation and reduced by theancer Cell 21, 105–120, January 17, 2012 ª2012 Elsevier Inc. 111
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sion in MDAPanc-28, AsPc-1, mPDAC-1, and mPDAC-2 cells
(Figures 7F–7H; Figure S4C), demonstrating that p62 expression
is regulated by NF-kB activity. To further demonstrate the regu-
lation of p62 expression by NF-kB, we identified two kB and
three AP-1 binding sites in both 3.0 kb human and mouse p62
promoters, which have extensive DNA sequence similarity (Fig-
ure 7I). The results from ChIP assays revealed that NF-kB BS2
and AP-1 BS3 sites showed higher binding activity upon IL-1a
stimulation in mPDAC-1 cells (Figure 7J). EMSA showed that
NF-kB BS2 site displayed the most kB binding activity, consis-
tent with the results of ChIP assay, whereas the three AP-1
binding sites showed similar binding activity in mPDAC-1 cells
(Figure S4D). The luciferase reporter gene assays, using different
p62 promoter constructs with and without mutated AP-1 or kB
binding sites and controls, showed that p62 expression is mainly
regulated by NF-kB activity through NF-kB BS2 site and is also
mediated by the three AP-1 sites in mPDAC cells, suggesting
that p62 is an NF-kB and AP-1 downstream target gene (Fig-
ure 7K). Furthermore, our results showed that NF-kB was acti-
vated in the KrasG12D PDAC model in the presence of wild-type
p53 function (Figures S4E and S4F), and FOXO3a was stabilized
and TSC1 was activated, whereas p70/S6K was not phosphory-
lated in IKK2/b knockdown cells (Figures S4G and S4H), sug-
gesting that both TSC1 and FOXO3a pathways is also involved
in Kras-induced PDAC development.
To demonstrated the role of IL-1a and p62 in mutant Kras-
driven cancer cells, we knocked down IL-1a and p62 expression
in mPDAC cells and in LKP-13, a lung adenocarcinoma cell line
derived from KrasG12D(LA1) mice (Wislez et al., 2005; Figure 8A;
Figures S5A and S5B), and showed significant reduction of
tumorigenic potential in the IL-1a and p62 knocked down cancer
cells in orthotopic xenograft mouse and subcutaneous xenograft
mouse models (Figures 8B-D). Knocking down TRAF6, which is
essential for IKK2/b and JNK activation in the IL-1a and TLR
pathways (Lomaga et al., 1999; Naito et al., 1999), decreased
NF-kB activation in both mPDAC cells expressing KrasG12D
(Figures 8E–8G). Taken together, these results suggest that
IL-1a and p62 play a key role in oncogenic Kras-induced tumors.
Knocking down of c-fos expression inhibited IL-1a and p62
expression and NF-kB activation (Figures 8H–8L). These resultsFigure 4. Gene Ontology and Gene Set Enrichment Analyses between
IKK2/bF/F Mice and Profiling Cytokine Expression
(A) Enriched expression of NF-kBdownstream target gene sets in Pdx1-Cre;KrasL
represents top enriched genes in Pdx1-Cre;KrasLSL-G12D;IKK2/bWT. NES, normaliz
q value. (red, high expression; blue, low expression).
(B) GSEA analyses identify the enriched gene sets expressed either in Pdx1-Cre
pathway gene sets. One gene set are enrich in Pdx1-Cre;KrasLSL-G12D;IKK2/bWT
Five NF-kB pathway-related gene sets are noteworthy enriched in Pdx1-Cre;Kr
significance (FDR q value < 0.25 and normalized p value < 0.05).
(C) GSEA analyses of significant gene upregulation in Pdx1-Cre;KrasLSL-G12D reve
tumor stage, and poor survival in PDAC patients by using 102 PDAC cDNA m
Cre;KrasLSL-G12D; IKK2/bF/F is correlated to low risk. ns, not significant (FDR q va
(D) Analysis of differential cytokine gene expression between pancreatic cancer a
age-matched Pdx1-Cre;KrasLSL-G12D;IKK2/bF/F mice) by real-time PCR arrays.
(E) Determination of IL-1a expression levels in pancreas, liver, and lung from Pdx1
wild-type (WT) mice.
(F) Evaluation of IL-1a and IL-1b expression levels in sera from Pdx1-Cre;KrasLSL-G
mice. Error bars represent ±SD of the data from three mice in each genotype as
Csuggest that AP-1 activated by oncogenic Kras induced and
sustained activation of RelA/p50 in PDAC development.
As illustrated in Figure 8M, our findings suggest a mechanism
bywhich oncogenic Kras signaling pathway induced constitutive
activation of NF-kB in PDAC development.
DISCUSSION
We have unequivocally demonstrated that the requirement of
NF-kB pathway for PDAC development and the mechanism
through which constitutive NF-kB activation and inflammatory
responses were induced by oncogenic Kras during PDAC
initiation. These findings suggest that the primum movens
responsible for cancer-related inflammatory responses and the
development of PanIN and PDAC is the mutant Kras-initiated
constitutive activation of NF-kB. Importantly, our results suggest
that mutant Kras may induce intrinsic inflammatory responses
that promote a protumorigenic microenvironment through
expressing inflammatory mediators such as chemokines and
cytokines in tumor tissues, recruiting inflammatory cells, and
inducing angiogenesis and tissue repair similar to those
observed in hereditary pancreatitis, which has been firmly linked
to the development of PDAC (Brentnall et al., 1999; Lowenfels
et al., 1997). Thus, our findings further suggest that sporadic
PDAC is also induced through a chronic inflammatory mecha-
nism similar to those observed in hereditary pancreatitis related
PDAC cases.
Although studies have demonstrated that mutant Ras was
shown to activate NF-kB in several types of tumors in mouse
models (Basse`res et al., 2010; Meylan et al., 2009; Yang et al.,
2010). Signaling pathways leading to the constitutive NF-kB
activity in cancer cells were not clear at all. Duran et al. (2008)
showed that mutant Ras induced p62 expression through AP-1
to activate IKK2/b and NF-kB. However, the requirement for
p62 in NF-kB activation is not completely understood consid-
ering the reported function of p62 as an adaptor for regulating
E3 ubiquitin-protein ligase TRAF6 and deubiquitination enzyme
CYLD to balance the turnover of K63-polyubiquitination
(Sanz et al., 2000; Wooten et al., 2005). Our results clearly
demonstrated that p62 expression is not required for rapid and
early NF-kB activation induced by IL-1a, but it is essential forPancreata from Pdx1-Cre;KrasLSL-G12D and Pdx1-Cre;KrasLSL-G12D;
SL-G12D;IKK2/bWT compared to Pdx1-Cre;KrasLSL-G12D;IKK2/bF/F. The heat map
ed enrichment score; NOM p value, nominal p value; FDR, false discovery rate
; KrasLSL-G12D;IKK2/bWT or Pdx1-Cre;KrasLSL-G12D;IKK2/bF/F using 198 KEGG
and twenty seven gene sets are enriched in Pdx1-Cre;KrasLSL-G12D;IKK2/bF/F.
asLSL-G12D; IKK2/bWT. Enriched gene sets were selected based on statistical
aled that they are strongly correlated to positive nodal status, high risk, higher
icroarray data (GSE21501). Two- and 5-fold enriched expression in Pdx1-
lue > 0.25 and/or normalized p value > 0.05).
nd normal pancreas (from 5- to 12-month-old Pdx1-Cre;KrasLSL-G12Dmice and
-Cre;KrasLSL-G12D, Pdx1-Cre;KrasLSL-G12D;IKK2/bF/F, Pdx1-Cre;IKK2/bF/F, and
12D, Pdx1-Cre;KrasLSL-G12D;IKK2/bF/F, Pdx1-Cre;IKK2/bF/F, andwild-type (WT)
indicated. See also Figure S2 and Tables S1–S3.
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Figure 5. Analysis of Signaling Pathways in PanIN, PDAC, and Histologically Normal Pancreas from Compound Mutant Mice and Human
PDAC Patients
(A) Immunohistochemical analysis with anti-IL-1a, anti-Rantes (Chemokine [C-C motif] ligand 5), anti-c-Fos, anti-TAK1, anti-p62, and anti-p65 antibodies in
sections of formalin-fixed PanIN lesions and PDAC from Pdx1-Cre;KrasLSL-G12D mice, and of normal duct tissues from Pdx1-Cre;KrasLSL-G12D;IKK2/bF/F mice.
Error bars represent ±SD from the data of five mice for each of the three genotypes.
(B) Immunohistochemical staining for IL-1a, TAK1, pAKT, c-Fos, p65, and p62 in sections of formalin-fixed human PDAC and adjacent histologically normal
pancreatic tissues. Error bars represent ±SD from six human PDAC specimens.
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KrasG12D-Induced IKK2 Activation and Tumorigenesisconstitutive NF-kB activation (Figure 7D; Figures S4A and S4B),
which is consistent with the function of p62 as an adaptor
for regulating the turnover of K63-polyubiquitinated proteins,
including TRAF6, to maintain IKK2/b and NF-kB activation
(Sanz et al., 2000; Wooten et al., 2005). Our results show that114 Cancer Cell 21, 105–120, January 17, 2012 ª2012 Elsevier Inc.expression of p62 is induced by NF-kB activation during IL-1a
stimulation of mouse and human PDAC cell lines (Figures 7E–
7J), suggesting the existence of an autoregulatory loop whereby
NF-kB regulates p62 expression, which, in turn, extends NF-kB
activation.
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Figure 6. Clinical Correlations among Mutant Kras, IL-a Overexpression, and NF-kB Activation in Human PDAC
(A) The percentages of IL-1a positivity in PDAC tissues carrying a mutant Kras gene. Chi-square test was used to demonstrate the positive correlation between
overexpression of IL-1a and the presence of a mutant Kras in PDAC tissues.
(B) Kaplan-Meier survival analysis of PDAC patients with and without high levels of IL-1a expression using TMA.
(C) Immunohistochemical staining for p65 and IL-1a in human PDAC tissue microarrays. Representative IHC stainings are shown, with four combinations of
immunostaining patterns, E1: p65 high, IL-1a high; E2: p65 high, IL-1a low; E3: p65 low, IL-1a high; E4: p65 low, IL-1a low.
(D) Scores of activated NF-kB are plotted against those of IL-1a overexpression. Spearman’s rank order correlation was used to demonstrate the positive
correlation between NF-kB activity and expression levels of IL-1a in TMA.
(E) Western blot analysis showing IL-1a and p62 overexpression in pancreatic cancer cell lines MDAPanc-28 and AsPc-1.
(F) Western blot analysis of IL-1a and p62 expression in hTERT-immortalized human pancreatic ductal HPNE and HPDE cell lines.
(G) Reporter gene assay for analyzing IL-1a promoter regulation by Kras, AP-1, and NF-kB pathways using mPDAC cells.
(H) Reporter gene assay for analyzing the regulation of p62 promoter by AP-1 and NF-kB pathways using mPDAC cells. Error bars represent ±SD from three
independent experiments. See also Figure S3.
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Figure 7. Elucidation of Feedforward Signaling Pathways that Sustain Constitutive NF-kB Activation in Oncogenic KrasG12D-Induced PDAC
(A) Nuclear extracts of human PDAC cell lines MDAPanc-28 and AsPc-1 and mouse PDAC cell lines mPDAC-1 and mPDAC-2 (derived from Pdx1-Cre;
KrasLSL-G12D), treated with anti-IL-1a neutralizing antibody (2 mg/ml) for 0, 4, or 8 hr or with anti-IL-1b neutralizing antibody (2 mg/ml) for 0 or 8 hr as indicated, were
analyzed by EMSA to determine NF-kB activity using a probe containing an NF-kB DNA binding site. Oct-1 DNA binding activities were determined as loading
controls.
(B) EMSAwas performed to determine the specificity of inducible RelA/p50 NF-kBDNAbinding activity. Competition and supershift assayswere performed using
20 mg of nuclear protein from mPDAC-2 cells as indicated.
(C) Western blot was performed to determine the expression of p62 in mPDAC cells (CTL), mPDAC cells (p62-shRNA) expressing p62shRNA, and mPDAC cells
(SB-shRNA) expressing scrambled control shRNA with anti-p62 antibody. Relative protein loading was determined by the use of anti-b-actin antibody.
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KrasG12D-Induced IKK2 Activation and TumorigenesisOur results show that TSC1 and FOXO3a pathways are
involved in Kras-induced PDAC (Figures S4G and S4H), consis-
tent with the studies showing that IKK2/b phosphorylates TSC1
at Ser487 and Ser511 and FOXO3a for promoting tumorigenesis
(Hu et al., 2004; Lee et al., 2007). Interestingly, expression of
both IL-1a and IL-1bwas inhibited in our Pdx1-Cre;KrasLSL-G12D;
IKK2/bF/F mouse model (Figures 4E–4F), pointing out different
regulatory mechanisms of IL-1b in pancreas as NF-kB activity
inhibits the release of IL-1b from macrophage (Greten et al.,
2007).
In summary, we report here constitutive NF-kB activation is
required for PDAC development and proposed the mechanism
for NF-kB activation by KrasG12D through AP-1-induced IL-1a
overexpression. Since IL-1a overexpression correlates with
poor survival in PDAC patients, and since it is found in other
diseases, such as chronic inflammation autoimmune disorders
(Gabay et al., 2010), pharmacologic targeting IL-1a overexpres-
sion may represent a potential therapy for PDAC.
EXPERIMENTAL PROCEDURES
Generation of Mouse Strain
The genetically engineered mouse strains used in our study were kindly and
generously provided by the following laboratories: floxed IKK2/b (IKK2/bF/F)
mice by Michael Karin’s laboratory (Li et al., 2003); floxed Ink4a/Arf (Ink4a/
ArfF/F) mice by Ronald Depinho’s laboratory (Aguirre et al., 2003); KrasLSL-G12D
mice by Tyler Jacks’ laboratory (Johnson et al., 2001); and Pdx1-Cre trans-
genic mice by Douglas Melton’s laboratory (Gu et al., 2002). These strains
were interbred to generate the experimental cohorts, which include the
following genotypes: Pdx1-Cre;KrasLSL-G12D, Pdx1-Cre;IKK2/bF/F, Pdx1-
Cre;KrasLSL-G12D; IKK2/bF/F, Pdx1-Cre;KrasLSL-G12D;Ink4a/ArfF/F and Pdx1-
Cre;KrasLSL-G12D;Ink4a/ArfF/F; IKK2/bF/F. These mutant mouse strains were
genotyped by PCR as previously described by the laboratories that generated
them. All animal experiments were conducted under the protocol that was
approved for this study by the Institutional Animal Care and Use Committee
(IACUC) at the University of Texas MD Anderson Cancer Center.
Patient Pancreatic Ductal Adenocarcinoma and Adjacent Normal
Tissues
Patient pancreatic cancer tissue microarray (TMA) was constructed and
paraffin sections were obtained using the paraffin blocks from primary pancre-
atic ductal adenocarcinoma and paired adjacent normal tissues of 131
pancreatic cancer patients, which were collected within 1 hr after surgery(D) NF-kB activities in the nuclear extracts of mPDAC cells (CTL), mPDAC cells (p
scrambled control shRNA stimulated with IL-1a for the times indicated were de
controls in (A) and (D).
(E) NF-kB-dependent expression of p62 was determined by western blot analys
tagged IkBamutant (Flag-IkBaM) and their control cells expressing a puromycin r
Flag antibody. Relative protein loading was determined by the use of anti-b-acti
(F) IL-1a-regulated p62 expression was determined by real-time PCR in MDAPa
antibody (2 mg/ml) for 8 hr or IL-1a (10 ng/ml) for 1 hr as indicated.
(G) IKK2/b-induced p62 expression was determined by western blot analysis u
b-shRNA (IKK2-shRNA) and their control cells expressing a puromycin resistance
verified by using anti-IKK2/b antibody. Relative protein loading was determined
(H) IL-1a-regulated p62 expression was determined by western blot analysis in pr
with anti-IL-1a neutralizing antibody (2 mg/ml) for 8 hr or IL-1a (10 ng/ml) for 1 h
antibody.
(I) The sequence alignment between mouse and human p62 promoter regions w
(J) The activities of the AP-1 and kB binding sites in mouse p62 promoter were det
were performed with anti-c-Fos and anti-p65/NF-kB antibodies and IgG as nega
(K) Analysis of p62 promoter activities in mPDAC-1 cells. The luciferase reporte
luciferase reporter constructs of the p62 promoter constructs with mutated AP-1
measured as described in Experimental Procedures. Error bars represent ±SD fr
Cunder the protocol approved by the Institutional Review Board at M.D. Ander-
son Cancer Center, and written informed consent was obtained from patients
in all cases at time of enrollment.
Cell Lines and Reagents
The human pancreatic cancer cell line AsPC-1 was purchased from the
American Type Culture Collection. MDAPanc-28 was established by Marsha
Frazier and Douglas B. Evans (M.D. Anderson Cancer Center). Immortalized/
nontumorigenic HPDE and the hTERT-HPNE cells were described (Lee
et al., 2005; Qian et al., 2005). Panc-28/ IkBaM, AsPc-1/IkBaM, HPNE/Kras,
and HPDE/Kras cell lines were established in Chiao’s laboratory (Qian et al.,
2005). Anti-human IL-1a and IL-1b, anti-mouse IL-1a and IL-1b neutralizing
antibodies, and IL-1a were obtained from R&D Systems.
Knockdown of IKK2/b, p62, IL-1a,Traf6, and c-Fos
To silence IKK2/b, p62, and IL-1a expression, DNA sequences encoding
shRNAs and a scramble sequence were chosen to clone into the FG12 lenti-
viral vector. The mouse primary pancreatic cancer cell lines mPDAC-1 and
mPDAC-2 and human PDAC cell lines Panc28 and AsPc-1 were infected by
lentivirus containing the shRNA. The infected cells were sorted by green fluo-
rescent protein after infection 4 days. The levels of target gene knockdown by
shRNA were determined using immunoblotting.
Statistical Analysis
Mean values between groups were compared by Excel. Survival curves were
plotted by the Kaplan-Meier method and compared by the log-rank test using
GraphPad Prism. The correlative relationships between two quantitative
measurements were investigated using Spearman rank-order correlation
and the chi-square statistic. Data were analyzed by the Student t test and
results were considered significant at a p value < 0.05.
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Microarray data has been deposited in the Gene Expression Omnibus (GEO)
database (accession number GSE33323).
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Figure 8. AP-1 Induced by Oncogenic KrasG12D Initiates Feedforward Loops of IL-1a and p62 to Induce and Sustain Constitutive NF-kB Acti-
vation and the Working Model
(A) Knocked down expression of IL-1a and p62 in mPDAC and LKP-13 cells. The expression levels of p62 and IL-1a in mPDAC and LKP-13 cells expressing
scrambled shRNA (SBshRNA), p62shRNA, and IL-1ashRNAwas determined using anti-p62 or anti- IL-1a antibody in western blot with b-actin as relative protein
loading controls.
(B) The resected orthotopic tumors attached to spleen in fifteen C57B6 mice injected with mPDAC-SBshRNA, mPDAC-p62shRNA, and mPDAC-IL-1ashRNA
cells (n = 5 per group) were shown at week 5. S: spleen; T: tumor.
(C) Tumor weight in C57B6 mice orthotopically injected with mPDAC-SBshRNA, mPDAC-p62shRNA, and mPDAC-IL-1ashRNA cells. Columns: mean of all
individual tumors in each group. Error bars: ±SD of the pancreatic tumor from five mice in each of the three groups as indicated.
(D) Percentage of C57B6 mice that developed subcutaneous tumors after injection of LKP-13-SB-shRNA, LKP-13-p62shRNA, and LKP-13-IL-1ashRNA cells.
Columns: percentage of the mice that grew tumor in each group (n = 5). The statistical significance was determined by Fisher’s exact test.
(E) Expression of TRAF6 in mPDAC cells expressing scrambled Traf6 shRNA (SB-shRNA) and two Traf6-shRNA (Traf6-shRNA-1 and 2) was determined by anti-
TRAF6 antibody with b-actin as loading control.
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